In collaboration with the Bill & Melinda Gates Foundation, PATH invites letters of interest and applications from technology manufacturers willing to provide eligible needle-free intradermal (ID) delivery devices for use in a clinical trial of reduced-dose inactivated polio vaccine (IPV) scheduled for 2013 in China.
Ensuring wide-scale access to IPV is a key goal of polio eradication efforts and post-eradication planning. The Bill & Melinda Gates Foundation plans to support a clinical trial to evaluate the dose-saving potential of IPV when it is delivered intradermally, which could extend vaccine supply and make IPV more affordable for immunization programs in developing countries. Needle-free delivery devices that facilitate safer, easier, and more consistent ID delivery of vaccine could also enable ID delivery of IPV by less-experienced health workers or trained volunteers.
To be eligible, devices must be needle free with a disposable, autodisabling fluid path and capable of delivering 0.1 ml of IPV intradermally in infants and children. Manually powered devices suitable for use either in a clinic or in a mobile campaign setting are preferred. Multiple devices that meet these requirements may be included in the trial.
Final device selections will be made by the Bill & Melinda Gates Foundation. Please also note that the Bill & Melinda Gates Foundation reserves the right to withdraw this request for applications and/or cancel the planned trial at any time.
Letters of interest are requested by April 27, 2012.
Full applications and supporting materials are due May 14, 2012.
Applications should include:
Please email the letter of interest and full application to email@example.com.
Relevant materials can also be mailed to:
PO Box 900922
Seattle, WA 98109
For questions and guidance on this opportunity, please contact PATH (primary) at firstname.lastname@example.org or Linda Venczel at email@example.com.